Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Alkali or alkaline earth chloride
Reexamination Certificate
2005-03-09
2011-11-01
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Alkali or alkaline earth chloride
C424S722000, C514S921000
Reexamination Certificate
active
08048454
ABSTRACT:
This invention relates generally to a method of treating inflammation and associated diseases and disorders by administering an agent that inhibits glycogen synthase kinase 3 activity.
REFERENCES:
patent: 4386072 (1983-05-01), Horrobin et al.
patent: 6441053 (2002-08-01), Klein et al.
patent: 2005/0075276 (2005-04-01), Rudd
patent: WO 98/17288 (1998-04-01), None
patent: WO 00/38675 (2000-07-01), None
Medline abstract, accession No. 1983257030 (1990).
Bagshawe, K.D., “The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites” Br. J. Cancer, 60:275-281, (1989).
Bagshawe, et al., “A cytotoxic agent can be generated selectively at cancer sites” Br. J. Cancer, 58:700-703, (1988).
Battelli, et al., “T lymphocyte killing by a xanthine-oxidase-containing immunotoxin” Cancer Immunol. Immunother., 35:421-425, (1992).
Berg, D. J., K. Kuhn, K. Rajewsky, W. Muller, S. Menon, N. Davidson, G. Grunig, and D. Rennick 1995. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance J. Clin. Invest. 96:2339-2347.
Brigham et al., “Expression of a prokaryotic gene in cultured lung endothelial cells after lipofection with a plasmid vector” Am. J. Resp. Cell. Mol. Biol. 1:95 100 (1989).
Brown and Greene, “Molecular and cellular mechanisms of receptor-mediated endocytosis” DNA and Cell Biology 10:6, 399-409 (1991).
Cichon (2001) “Complement activation by recombinant adenoviruses” Gene Ther 8:1794-1800.
Cohen (2002) “The immunopathogenesis of sepsis”Nature420(6917):885-91.
Cohen, “The role of protein phosphorylation in human health and disease”Eur. J. Biochem.268:5001-5010 (2001).
Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature. 378:785-789.
Cross, D. A., A. A. Culbert, K. A. Chalmers, L. Facci, S. D. Skaper, and A. D. Reith 2001. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death J. Neurochem. 77:94-102.
Demarchi et al., “Gas6 anti-apoptotic signaling requires NF-kappaB activation” J. Biol. Chem. 276:31738-31744 (2001).
Demarchi et al., “Glycogen synthase kinase-3 beta regulates NF-kappaB1/p105 stability” J. Biol. Chem. 278:39583-90 (2003).
Doble and Woodgett “GSK-3: trickes of the trade for a multi-tasking kinase” J. Cell Sci. 116:1175-86 (2003).
Dinarello, C. A. 2000. “Proinflammatory cytokines” Chest. 118:503-508.
Feghali et al., “Cytokines in acute and chronic inflammation” Frontiers in Bioscience 2, d12-26, Jan. 1, 1997.
Franke, T. F., D. R. Kaplan, L. C. Cantley, and A. Toker 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate Science. 275:665-668.
Fukao, T., M. Tanabe, Y. Terauchi, T. Ota, S. Matsuda, T. Asano, T. Kadowaki, T. Takeuchi, and S. Koyasu 2002. PI3K-mediated negative feedback regulation of IL-12 production in DCs Nat. Immunol. 3:875-881.
Fukao, T., T. Yamada, M. Tanabe, Y. Terauchi, T. Ota, T. Takayama, T. Asano, T. Takeuchi, T. Kadowaki, J. J. Hata, and S. Koyasu 2002. Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat Immunol. 3:295-304.
Ghosh et al., “NF-kappaB and rel proteins: evolutionary conserved mediators of immune responses” Annu. Rev. Immunol. 16:225-260 (1998).
Grimes and Jope “CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium” J. Neurochem. 78:1219-1232 (2001).
Guha, M., and N. Mackman 2002. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells J. Biol. Chem. 277:32124-32132.
Han, S. H., J. H. Kim, M. Martin, S. M. Michalek, and M. H. Nahm 2003. Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2 Infect. Immun. 71:5541-5548.
Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2 J. Immunol. 165:618-622.
Hirschfeld, M., J. J. Weis, V. Toshchakov, C. A. Salkowski, M. J. Cody, D. C. Ward, N. Qureshi, S. M. Michalek, and S. N. Vogel 2001. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages Infect. Immun. 69:1477-1482.
Hoeflich et al., “Requirement for glycogen synthase kinase-3 beta in cell survival and NF-kappaB activation” Nature 406:86-90 (2000).
Howard, M., T. Muchamuel, S. Andrade, and S. Menon 1993. Interleukin 10 protects mice from lethal endotoxemia J. Exp. Med. 177:1205-1208.
Jooss, K. (2003) “Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy” Gene Ther. 10:955-963.
Kim et al., “Glycogen synthase kinase 3beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1)”Journal of Biological Chemistry278(16):13995-14001 (2003).
Klein and Melton “A molecular mechanism for the effect of lithium on development” PNAS 93:8455-59 (1996).
Kunick et al., “1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta” Bioorg. Med. Chem. Lett. 19:413-6 (2004).
Lawlor, M. A., and D. R. Alessi 2001. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell. Sci. 114:2903-2910.
Martin, M., R. E. Schifferle, N. Cuesta, S. N. Vogel, J. Katz, and S. M. Michalek 2003. Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide J. Immunol. 171:717-725.
Meijer et al., “GSK-3 selective inhibitors derived from Tyrian purple indirubins” Chem. Biol. 10:1255-66 (2003).
Morton et al., “A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun”EMBO Journal22(15):3876-3886 (2003).
Nemeth et al., “Lithium induces NF-kappaB activation and interleukin-8 production in human intestinal epithelial cells” J. Biol. Chem. 277:7713-9 (2002).
O'Neill, L. A., and C. A. Dinarello 2000. The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense Immunol. Today. 21:206-209.
Parker et al., “Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism” Mol. Cell Biol. 16:694-703 (1996).
Parry and Mackman “Role of cyclic AMP response element binding protein in cyclic AMP inhibition of NV-kappaB-mediated mechanism” J. Immunol. 159:5450-6 (1997).
Pietersz and McKenzie, “Antibody conjugates for the treatment of cancer” Immunolog. Reviews, 129:57-80, (1992).
Platzer et al., “Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells” Eur. J. Immunol. 29:3098-3104 (1999).
Roffler, et al., “Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate” Biochem. Pharmacol, 42:2062-2065, (1991).
Schwabe and Brenner “Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes” Am. J. Physiol. Gastrointest. Liver Physiol. 283:G204-G211 (2002).
Senter, et al., “Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates” Bioconjugate Chem., 2:447-451, (1991).
Senter, et al., “Generation of cytotoxic agents by targeted enzymes” Bioconjugate Chem., 4:3-9, (1993).
Sheppard et al., “Transcriptional activation by NF-kappaB requires multi
Black C. Allen
Pak John
LandOfFree
Methods and compositions related to regulation of cytokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions related to regulation of cytokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions related to regulation of cytokine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4305213